PROCARDIA XL (nifedipine) by Pfizer is calcium channel antagonists [moa]. First approved in 1989.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
PROCARDIA XL is an extended-release oral tablet formulation of nifedipine, a dihydropyridine calcium channel blocker approved in 1989. It works by antagonizing calcium channels to reduce vascular smooth muscle contraction, lowering blood pressure and reducing myocardial oxygen demand. It is indicated for hypertension and angina pectoris.
Mature product approaching loss of exclusivity with declining revenue signals contraction of brand team and shift toward generic optimization support.
Calcium Channel Antagonists
Dihydropyridine Calcium Channel Blocker
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil
Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients, a Prospective, Multicenter, Observational Study
Comparison of Nifedipine Versus Indomethacin for Acute Preterm Labor
Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness
REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial
Worked on PROCARDIA XL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPROCARDIA XL offers limited career growth potential due to mature lifecycle and approaching LOE; roles focus on defending market share, managing payer relationships, and optimizing generic transition rather than driving innovation or launches. Career value lies in operational excellence and cost-containment expertise rather than brand-building or clinical development.